Morning tea 04-11-2015

1. SEBI Certified – Research Analyst www.choiceindia.com
Global View
India Update
Today’s Event/ Stock in News
Pharma Major Lupin has received final approval for its Donepezil Hydrochloride Tablets, 23 mg from the United States Food and
Drug Administration (US FDA) to market a generic version of Eisai Inc.'s Aricept Tablets, 23mg. Lupin's US subsidiary, Lupin
Pharmaceuticals Inc. would commence promoting the product shortly in the US. Lupin's Donepezil Hydrochloride Tablets, 23 mg
are the AB rated generic equivalent of Eisai Inc.'s Aricept Tablets, 23mg and is indicated for the treatment of dementia of the
Alzheimer's type. Aricept had US sales of $52.3 million (IMS MAT June 2015). Lupin is an innovation led transnational
pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and
APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective
and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Technical Outlook : The stock is trading near to its support of breakout trend line at 1854 levels on daily chart, from where bounce
back can be seen in the stock. Moreover, stock has been trading above100 DEMA on daily chart which indicates that medium to
long term trend is up. A momentum indictor RSI has moved in oversold zone territory zone which point out for bounce back in
the prices. So for trading perspective, one could Buy in the range of 1862-1875 for the Target of 1915 with the SL of 1842.
LUPIN
SMLISUZU
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Morning Tea
04th Nov 2015
Buy in the range of 1345-1355 for the Target of 1385 with the SL of 1330
Buy in the range of 1862-1875 for the Target of 1915 with the SL of 1842
SML Isuzu has reported 41.51% rise in October sales. The company has sold 784 vehicles during October, 2015 against 554
vehicles sold in October, 2014. SML Isuzu manufactures a range of vehicles such as trucks, buses and ambulances. The company
has launched products like 4WD, Samrat, Sartaj, Dual Cab, Supreme-8 tonner, Truck- Super 12, Super ALFD and many more.
Technical Outlook:Ondailychart, recentlythe stockhas takensupportof1295 level andgave goodupside movement. Moreover, stockhasbeen
tradingabove21DEMAondailychart,whichindicatesthatshorttermtrendisup.AmomentumindictorRSIhasremainedabove40levelsondaily
chart, which point out for positive breath in the stock. So for trading perspective, one could Buy in the range of 1345-1355 for the Target of 1385
withtheSLof1330.
Asian stocks rallied early Wednesday, thanks to a positive lead from Wall Street and firmer crude oil prices. Overnight, a fifth
straight day of gains for energy counters alongside a rise in tech majors helped propel major US averages. Shanghai Composite
index traded at 1.60% to 3370.78, Hang Seng index traded at 2.85 % to 23229.67, Japan's benchmark Nikkei 225 index traded at
2.36% to 19134.92, South Korea's Kospi index traded marginally up by 0.19 % to 2052.33 levels. The SGX Nifty suggests a gap up
opening for our markets as it is trading at 8149.50, up by 74.00 points.
Global markets may lend their support to the Dalal Street with US markets closing higher supported by gains in energy and tech
stocks. The three major indexes continued a positive start for November, after posting their best monthly performances in four
years in October. The S&P energy sector rose 2.5 percent, its fifth straight daily increase, as crude prices rallied. Oil majors Exxon
and Chevron rose 1.8 percent and 3.3 percent, respectively, making both stocks among the top influences on the Dow and S&P.
In Europe, a rally in oil prices helped shake off weak earnings results from the likes of UBS and Standard Chartered. The Dow
Jones industrial average rose 89.39 points, or 0.5 percent, to 17,918.15, the S&P 500 gained 5.74 points, or 0.27 percent, to
2,109.79 and the Nasdaq Composite added 17.98 points, or 0.35 percent, to 5,145.13.

2. SEBI Certified – Research Analyst www.choiceindia.com
Bulk Deal
Corporate Action / Result Calendar
SEBI Certified – Research Analyst www.choiceindia.com
Morning Tea
Corporate Action:
Result Calendar:
ASHOKLEY, BAJAJHIND, BATAINDIA, CANBK, CENTURYPLY, CHENNPETRO, ENGINERSIN, ESSARPORTS,
FORTIS, GODREJPROP, HONAUT, IDBI, JAICORPLTD, JBCHEPHARM, KSBPUMPS, MAGMA, MAHABANK,
MANALIPETC, MARICO, NEYVELILIG, PGHH, PRICOL, RELINFRA, REPCOHOME, SADBHAV, SCI, SPARC,
VOLTAMP, WHIRLPOOL.
04th Nov 2015
Security in Ban
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Sr.No Deal Date Security Code Security Name Client Name Deal Type Quantity Price
1 3/11/2015 532348 SUBEX QVT MAURITIUS WEST FUND S 3500000 11.29
2 3/11/2015 532348 SUBEX MERRILL LYNCH CAPITAL MARKETS ESPANA SA SV S 1680000 11.05
3 3/11/2015 502465 SPECIAPP ANVITA REAL ESTATE PRIVATE LIMITED B 902226 0.90
4 3/11/2015 502465 SPECIAPP MERITORIOUS REALTY PRIVATE LIMITED S 899000 0.90
5 3/11/2015 522209 YOGISUNG KAMLESHBHAI RAMESHBHAI LUNAGARIYA S 349757 9.25
6 3/11/2015 522209 YOGISUNG KAMLESHBHAI RAMESHBHAI LUNAGARIYA B 349757 9.33
7 3/11/2015 522209 YOGISUNG MADHUBEN HARISHKUMAR PRAJAPATI S 319678 9.71
8 3/11/2015 522209 YOGISUNG MADHUBEN HARISHKUMAR PRAJAPATI B 319678 9.71
9 3/11/2015 522209 YOGISUNG ANITA SANDEEP KUMAR PARMAR S 296135 9.69
10 3/11/2015 522209 YOGISUNG ANITA SANDEEP KUMAR PARMAR B 296135 9.69

3. SEBI Certified – Research Analyst www.choiceindia.com
Contact Us
www.choiceindia.com
www.choiceindia.comcustomercare@choiceindia.com
Disclaimer
This is solely for information of clients of Choice Broking and does not construe to be an investment advice. It is also not intended as an offer or solicitation for the purchase and sale of any financial
instruments. Any action taken by you on the basis of the information contained herein is your responsibility alone and Choice Broking its subsidiaries or its employees or associates will not be liable in
any manner for the consequences of such action taken by you. We have exercised due diligence in checking the correctness and authenticity of the information contained in this recommendation, but
Choice Broking or any of its subsidiaries or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the
information contained in this recommendation or any action taken on basis of this information. Technical analysis studies market psychology, price patterns and volume levels. It is used to forecast
future price and market movements. Technical analysis is complementary to fundamental analysis and news sources. The recommendations issued herewith might be contrary to recommendations
issued by Choice Broking in the company research undertaken as the recommendations stated in this report is derived purely from technical analysis. Choice Broking has based this document on
information obtained from sources it believes to be reliable but which it has not independently verified; Choice Broking makes no guarantee, representation or warranty and accepts no responsibility
or liability as to its accuracy or completeness. The opinions contained within the report are based upon publicly available information at the time of publication and are subject to change without
notice. The information and any disclosures provided herein are in summary form and have been prepared for informational purposes. The recommendations and suggested price levels are intended
purely for trading purposes. The recommendations are valid for the day of the report however trading trends and volumes might vary substantially on an intraday basis and the recommendations may
be subject to change. The information and any disclosures provided herein may be considered confidential. Any use, distribution, modification, copying, forwarding or disclosure by any person is
strictly prohibited. The information and any disclosures provided herein do not constitute a solicitation or offer to purchase or sell any security or other financial product or instrument. The current
performance may be unaudited. Past performance does not guarantee future returns. There can be no assurance that investments will achieve any targeted rates of return, and there is no guarantee
against the loss of your entire investment.
POTENTIAL CONFLICT OF INTEREST DISCLOSURE (as on date of report) Disclosure of interest statement – • Analyst interest of the stock /Instrument(s): - No. • Firm interest of the stock /
Instrument (s): - No.
SEBI Certified – Research Analyst www.choiceindia.com
Research Team
Mr. Sumeet Bagadia Associate Director
Kunal Parmar Research Associate
Amit Pathania Research Associate
Vikas Chaudhari Research Associate
Rajnath Yadav Research Associate
Satish Kumar Research Associate
Morning Tea
04th Nov 2015
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Kunal Parmar
Digitally signed by Kunal Parmar
DN: cn=Kunal Parmar, o=Choice Equity Broking Pvt
Ltd., ou=Research Dept.,
email=kunal.parmar@choiceindia.com, c=IN
Date: 2015.11.04 09:02:56 +05'30'